JP2020502224A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502224A5
JP2020502224A5 JP2019533666A JP2019533666A JP2020502224A5 JP 2020502224 A5 JP2020502224 A5 JP 2020502224A5 JP 2019533666 A JP2019533666 A JP 2019533666A JP 2019533666 A JP2019533666 A JP 2019533666A JP 2020502224 A5 JP2020502224 A5 JP 2020502224A5
Authority
JP
Japan
Prior art keywords
crystal
crystalline form
purity
composition according
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019533666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502224A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2017/045731 external-priority patent/WO2018117153A1/en
Publication of JP2020502224A publication Critical patent/JP2020502224A/ja
Publication of JP2020502224A5 publication Critical patent/JP2020502224A5/ja
Priority to JP2022207814A priority Critical patent/JP2023024729A/ja
Priority to JP2024134769A priority patent/JP2024161449A/ja
Pending legal-status Critical Current

Links

JP2019533666A 2016-12-21 2017-12-20 ヤヌスキナーゼ阻害剤の結晶形 Pending JP2020502224A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022207814A JP2023024729A (ja) 2016-12-21 2022-12-26 ヤヌスキナーゼ阻害剤の結晶形
JP2024134769A JP2024161449A (ja) 2016-12-21 2024-08-13 ヤヌスキナーゼ阻害剤の結晶形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437262P 2016-12-21 2016-12-21
US62/437,262 2016-12-21
PCT/JP2017/045731 WO2018117153A1 (en) 2016-12-21 2017-12-20 Crystalline forms of a janus kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022207814A Division JP2023024729A (ja) 2016-12-21 2022-12-26 ヤヌスキナーゼ阻害剤の結晶形

Publications (2)

Publication Number Publication Date
JP2020502224A JP2020502224A (ja) 2020-01-23
JP2020502224A5 true JP2020502224A5 (OSRAM) 2021-02-04

Family

ID=60991475

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019533666A Pending JP2020502224A (ja) 2016-12-21 2017-12-20 ヤヌスキナーゼ阻害剤の結晶形
JP2022207814A Pending JP2023024729A (ja) 2016-12-21 2022-12-26 ヤヌスキナーゼ阻害剤の結晶形
JP2024134769A Pending JP2024161449A (ja) 2016-12-21 2024-08-13 ヤヌスキナーゼ阻害剤の結晶形

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022207814A Pending JP2023024729A (ja) 2016-12-21 2022-12-26 ヤヌスキナーゼ阻害剤の結晶形
JP2024134769A Pending JP2024161449A (ja) 2016-12-21 2024-08-13 ヤヌスキナーゼ阻害剤の結晶形

Country Status (13)

Country Link
US (1) US11339181B2 (OSRAM)
EP (1) EP3559003B1 (OSRAM)
JP (3) JP2020502224A (OSRAM)
KR (1) KR102788829B1 (OSRAM)
CN (2) CN110325536A (OSRAM)
AU (1) AU2017380213B2 (OSRAM)
BR (1) BR112019012210A2 (OSRAM)
CA (1) CA3044771A1 (OSRAM)
ES (1) ES2926986T3 (OSRAM)
IL (1) IL267393B2 (OSRAM)
MX (1) MX386181B (OSRAM)
TW (1) TWI822666B (OSRAM)
WO (1) WO2018117153A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288080B2 (en) 2016-12-21 2024-03-01 Leo Pharma As A process for the preparation of H7-pyrrolo[3,2-d]pyrimidine derivatives and their artificial intermediates
CN118903144A (zh) * 2019-08-07 2024-11-08 乐敦制药株式会社 泪液分泌促进用眼科组合物
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
WO2023009767A1 (en) * 2021-07-30 2023-02-02 Eli Lilly And Company Treatment of hand eczema with baricitinib
IL322047A (en) 2023-02-28 2025-09-01 Assia Chem Ind Ltd Solid forms of dalgocitinib and processes for their preparation
WO2024225445A1 (en) * 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080022173A (ko) * 2005-07-07 2008-03-10 톰슨 라이센싱 평면 스크린 디스플레이 시스템 그리고 상응하는 슬리브들
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
DK2432472T3 (da) * 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
JP6427497B2 (ja) * 2013-10-21 2018-11-21 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
KR20180025940A (ko) 2015-07-07 2018-03-09 니뽄 다바코 산교 가부시키가이샤 7H-피롤로[2,3-d]피리미딘 유도체의 제조 방법 및 그의 중간체

Similar Documents

Publication Publication Date Title
JP2020502224A5 (OSRAM)
AU2022201072A1 (en) Compositions and methods for inhibiting arginase activity
CA2800541C (en) Soluble guanylate cyclase activators
JP2015512942A5 (OSRAM)
TW201100426A (en) New compounds for the treatment of CNS disorders
KR102345381B1 (ko) 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
ES2351958T3 (es) 5-cloro-3-(4-metanosulfonilfenil)-6'-metil-[2,3'] bipiridinil en forma cristalina pura y procedimiento de síntesis.
JP2016528179A (ja) 製造方法及びmdm2阻害剤の結晶形
JP2018035160A5 (OSRAM)
CL2008002184A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension pulmonar, osteoporosis, artritis, entre otras.
JP6592512B2 (ja) 三環式アトロプ異性体の化合物
JP2011523412A5 (OSRAM)
ME02612B (me) Tenofovir alafenamid hemifumarat
JP2020525512A (ja) 癌および他の疾患を処置するためのATF4阻害剤としての2−(4−クロロフェノキシ)−N−((1−(2−(4−クロロフェノキシ)エチンアゼチジン(ethynazetidin)−3−イル)メチル)アセトアミド誘導体および関連化合物
TW201209026A (en) Process for the preparation of pleuromutilins
CN102131809A (zh) 三环吡唑并吡啶激酶抑制剂
JP2018514544A (ja) Rsv抗ウイルス性ピラゾロおよびトリアゾロピリミジン化合物
JP2009502780A5 (OSRAM)
PH12017501690A1 (en) Crystal of 3,5-disubstituted benzene alkynyl compound
MX2012003720A (es) N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[ 1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)a cetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos.
JP2015522037A5 (OSRAM)
JP2011527687A5 (OSRAM)
JPWO2021033729A5 (OSRAM)
JP2013520488A5 (OSRAM)
JP2016515550A5 (OSRAM)